

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Commissioner for Patents Box Patent Application **9**. O. Box 1450 . Alexandria, VA 22313-1450 Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: MO1720 US CNT 4 INVENTORS: Mitsuo Nakamura, et al TITLE:PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THEOPTICAL RESOLUTION OF RACEMIC ALPHA-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINESBUTANOL AND DERIVATIVE COMPOUNDS

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231,

APP	APPLICATION ELEMENTS									
1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)								
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	75						
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets							
4.	Oath a.	or Declaration Newly executed (original or copy)	Total Pages	2						
	b.	Copy from a prior application (37 CFR § 1 (for continuation/divisional with Box 16 completed)	.63(d))							
		i. DELETION OF INVENTOR(S) Signed statement attached deleting is application, see 37 CFR §§ 1.63(d)(2)		ned in the prior						
5.		Microfiche Computer Program (Appendix)								
6.		eotide and/or Amino Acid Sequence Submission licable, all necessary) Computer Readable Copy Paper Copy (identical to computer copy) Statement verifying identity of above copie	es							

	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no:10/192,444, filed July 10,2002, Examiner C. Chang, Group/Art Unit 1625. (The cross reference has been/will be inserted on page one of the specification).						
	This application claims the benefit of U.S. Provisional Application No. , filed . (The cross reference has been/will be inserted on page one of the specification).						
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
ACC	OMPANYING APPLICATION PARTS						
7. 8.	Assignment Papers (cover sheet & document(s)) 37 CFR §3.73(b) Statement Power of (when there is an assignee) Attorney						
9.	English Translation Document (if applicable)						
10.	Information Disclosure Copies of IDS Statement (IDS)/PTO-1449 Citations						
11.	Preliminary Amendment						
12.	Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
13.	*Small Entity Statement(s) Statement filed in prior application, (PTO/SB/09-12) Status still proper and desired						
14.	Certified Copy of Priority Document(s) (if foreign priority is claimed)						
15.	Other: E-Pave; Copy of Extension of Time MO1720USCNT3						
COR	RESPONDENCE ADDRESS						
	005487						
\boxtimes	Customer Number or Bar Code Label						
	(Insert Customer No. or Attach bar code label here)						
	Balone E. Kan						
	Barbara E. Kurys, Reg No. 34,650 Attorney/Agent for Applicant						
	ntis Pharmaceuticals Inc.						
	nt Department te #202-206 / P.O. Box 6800						
Bridg	gewater, New Jersey 08807-0800						
Tele Tele	phone (908) 231-2965 fax (908) 231-2626						

Aventis Docket No. MO 1720 US CNT 4

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

CCC TDANCMITTAL

Fee

Extra

Complete if Known

74			117		OIAII I	IAL		Appl	ication N	umber	NOT YET ASSIGNED	
7414			£		2004			Filing	g Date		FILED HEREWITH	
-			TOL	ΓY	2004	•		First	Named I	nventor	MITSUO NAKAMUAR, ET AL	
\subseteq					t to annual revis			Exar	niner Na	me	C. CHANG	
رداق	Applica	nt claims	s small (entity sta	tus. See 37 (CFR 1.27		Grou	ıp / Art U	nit	1625	
TOTA	L AM	OUNT	OF PA	YMENT	(\$) 2,004.0	0	Attorney Docket No. MO 1720 US CNT 4				
0			2 40									
M	ETHO	DD OF	PAYM	ENT (c	heck all that a	apply)			FE	E CAL	CULATION (continued)	
Ched	ck [Credit C	ard [Money Order	Other	None .	3. AI	ODITIO	NAL F	EES		
Dep	osit Acc	ount					Large E	ntity	Small E	ntity		
Deposit Account				18-1	982		Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Number Deposit		<u> </u>									Fee Description	Fee Paid
Account		-	Aventis	Pharm	aceuticals In	c.			2251			
Name The Co	mmiss	Lioner is	author	ized to:	(check all tha	t apply)	1051	130	2051	65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or	ļ
K-2		s) indicate			Credit any over		1052	50	2052	25	cover sheet	l
	•	•			endency of this	,	1053	130	1053	130	Non-English Specification	
=	•				-		1812 1804	2,520 920*	1812 1804	2,520 920*	For filing a request for reexamination Requesting publication of SIR prior to	<u> </u>
		s) indicati e-identifie			or the filing fee	•	1004	920	1004	920	Examiner action	
				CULAT	TION		1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BAS	SIC FI	LING F	EE				1251	110	2251	55	Extension for reply within first month	
Large E			Entity			Fee		400				
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee De	scription	Paid	1252	420	2252	205	Extension for reply within second month	1
1001	770	2001	375	Utility fil	ling fee	770	1253	950	2253	465	Extension for reply within third month	
1002	340	2002	165	Design	filing Fee		1254	1,480	2254	725	Extension for reply within fourth month	
1003	530	2003	260	Plant fili	ing fee		1255	2,010	2255	985	Extension for reply within fifth month	
1004	770	2004	375	Reissue	e filing fee		1401	330	2401	160	Notice of Appeal	
1005	160	2005	80	Provisio	nal filing fee		1402	330	2402	160	Filing a brief in support of an appeal	
		SUE	втота	L (1)	(\$)770		1403	290	2403	140	Request for oral hearing	
2. EX1	ra c			• •	LITY AND F	REISSUE	1451	1,510	1451	1,510	Petition to institute a public use proceeding	

from Fee Claims below Paid Total Claims 36 288 1453 1.330 2453 Petition to revive - unintentional -20* 16 18 650 Independent 14 - 3**= 11 86 946 1501 1,330 2501 650 Utility issue fee (or reissue) 2502 1502 480 235 Design issue fee Multiple Dependent 1503 640 2503 315 Plant issue fee 1460 130 1460 130 Petitions to the Commissioner Large Entity **Small Entity** 1807 1807 50 Petitions related to provisional 50 Fee applications Code (\$) Code (\$) Fee Description 1806 180 1806 180 Submission of Information Disclosure 1202 18 2202 9 Claims in excess of 20 Independent claims in excess of 3 8021 40 8021 40 Recording each patent assignment per 1201 86 2201 42 property (times number of properties) 1203 290 2203 140 Multiple dependent claim, if not 1809 770 2809 375 Filing a submission after final rejection paid
**Reissue independent (37 ČFR § 1.129(a)) 770 2810 For each additional invention to be 1204 86 2204 42 1810 375 examined (37 CFR § 1.129(b)) claims over original patent 1205 18 2205 9 Reissue claims in excess of 1801 770 2801 375 Request for Continued Examination 20 and over original patent Request for expedited examination of a 1802 900 1802 900 design application SUBTOTAL (2) (\$)1234.00 Other fee (specify) **or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid SUBTOTAL (3)

1452

2452

55

Petition to revive - unavoidable

110

SUBMITTED BY			Complete (If applicable)			
Name (Print/Type)	Barbara E. Kurys	Registration No. (Attorney/Agent)	34,650	Telephone	(908) 231-2965	
Signature	Balone E. King			Date	1/29/04	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.